IN8BIO INC

INABNASDAQ

🏆 #3928 by market capEarnings Nov 5US Equity

$1.05▲ $0.08 (+7.73%)

🌙 After hours$1.01▼ 3.76%Regular close · extended-hours price shown

1h—

24h▲ 7.7%

7d▲ 8.9%

14d▼ 9.5%

30d▼ 19.8%

1y▼ 53.7%

🏦Market Cap

$10M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $1.03 – $1.05
52-Week Range: $0.90 – $2.73
Volume: $1.82B
Avg Volume: $1.32B
Shares Outstanding: 9.8M
Next Earnings: Sep 21, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $732,148
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.04
Dividend Yield: —

Why Investors Own INAB

✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▲ +12.5% YoY

Gross Margin (TTM)

52.8%▲ +1.7% YoY

Operating Income (TTM)

$1M▲ +12.5% YoY

Free Cash Flow (TTM)

$827,400▲ +12.5% YoY

About IN8BIO INC

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

🦦